The Nomination committee for Dicot AB appointed

Press release: Uppsala, November 3, 2022. According to decision at the Annual General Meeting of Dicot AB on May 24, 2022, the Nomination committee for the Annual General Meeting on May 23, 2023, shall consist of three members representing the three largest shareholders as of the end of September 2022.

Based on the above, the Nomination committee for the 2023 Annual General Meeting (AGM) has been appointed with the following three members:

  • Bertil Lindkvist
  • Tore Robertsson
  • Arne Paalberg

The Nomination committee shall submit proposals for decisions regarding the following subjects for the AGM on May 23, 2023:

a. Election of chairman at the AGM.
b. Determination of number of board members.
c. Determination of fees and other compensation for the board and its committees, divided between the chairman and other board members.
d. Determination of fees for auditors.
e. Election of board members and chairman of the board.
f. Election of auditors.
g. Principles for the Nomination committee's composition and work ahead of the 2024 AGM.

Shareholders who wish to submit proposals to the Nomination committee can do so via e-mail to:

In order for the Nomination committee to be able to consider proposals, the proposal must have been received in good time before the AGM, but no later than March 31, 2023.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit


Uppsala, March 28, 2023. Dicot has now conducted the last of two planned regulatory meetings prior to an application to start clinical trials. The purpose was to anchor the scientific background documentation to be included in a clinical trial application and covered central parts of Dicot's study design to which the Swedish Medical Product Agency was positive.


Press release: Uppsala, Sweden, March 8, 2023. Dicot has entered into a consultancy agreement with medical doctor Harin Padma-Nathan, a world leading medical expert in male sexual dysfunctions. Dr Padma-Nathan was involved in the development of the drugs for erectile dysfunction currently on the market, e.g., as Lead Principal Investigator during the development of Viagra and Cialis. His Viagra paper in The New England Journal of Medicine is the most cited paper in the field of urology.


Press release: Uppsala, February 27, 2023. Dicot AB (publ) hereby publishes its year-end report for the period January - December 2022 and for the fourth quarter. The year-end report is available  as an attached document and on the company's website Below is a summary of the report.

Fourth quarter 2022

  • Net sales amounts to KSEK 0 (0)
  • Earnings after financial items amounts to KSEK -8,604 (-8,408)
  • Earnings per share amounts to SEK -0.06 (-0.10)

January - December 2022

  • Net sales amounts to KSEK 0 (0)
  • Earnings after financial items amounts to KSEK -31,756 (-27,175)
  • Earnings per share amounts to SEK -0.26 (-0.42)

Press release: Uppsala, February 20, 2023. Dicot announces that the GMP manufacturing of the study drug for the planned phase 1 studies has begun. This is completely in line with the company's time schedule for start of clinical studies. The manufacture refers to both study drugs with active substance and placebo.


Uppsala, February 17, 2023. Today the pharmaceutical company Dicot presented the latest study of the mechanism of action of LIB-01 at the European Society for Sexual Medicine's annual congress in Rotterdam. The study shows that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors, and that LIB-01 may thus represent a completely new generation of potency drugs.


Uppsala, January 23, 2023. The pharmaceutical company Dicot AB that develops LIB-01 to become a new potency drug, today announces that it is moving forward with a new patent application. The patent application covers the new oral formulation for LIB-01 that was developed in 2022 and which will be used in the phase 1 clinical studies. This follows the IP strategy earlier communicated by the company.


Press release: Uppsala, January 19, 2023. The pharmaceutical company Dicot has contracted Thermo Fisher Scientific, the world leader in serving science, to perform GMP manufacturing of the drug candidate LIB-01 for the upcoming clinical trials.


Uppsala, January 4, 2023. The pharmaceutical company Dicot announces the contracting of reputable Clinical Trial Consultants AB (CTC) for conducting clinical phase 1 studies intended to start in mid-2023. The studies will take place at the contracted company's research clinic in Uppsala.


Uppsala, December 8, 2022. The pharmaceutical company Dicot announces that results from the latest study of the mechanism of action of LIB-01 have been selected to be presented at the European Society for Sexual Medicine's annual congress in February 2023.


Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs.